Forecast Next Dividend Date: Friday 05 April 2019
Days remaining until next forecast dividend: 13
This is only a forecast. Forecast ex-dividend dates are taken from company's website or by using previous ex-dividend dates as a guide. Please confirm ex-dividend date with your broker.
Dividend Star Rating for CYCLOPHARM LIMITED(CYC)
Fundamental Data for CYCLOPHARM LIMITED(CYC)Sector: Diversified Financials Price: $1.14 (delayed) Year High: $1.30 Year Low: $0.85 Market Capitalisation: $0.076 billion Net Tangible Assets: $0.18 billion Earnings per Share: 0.18 cents Price Earnings Ratio: 0 Forecast Earnings Growth (5 years): 0% per annum Dividend Cover: 0
Dividend Payment History for CYCLOPHARM LIMITED(CYC)
|Ex-Dividend Date||Books Close Date||Date Payable||Amount||Franking||Franking Credit||Gross Dividend||Cum Div Price||Gross Yield||RoI|
- Care should be taken interpreting this chart as all dividend payments for final year may not have been paid.
- The financial year that the dividend is allocated depends on the payment date of the dividend, not the ex-dividend date.
- Dividend history has not been adjusted for any capital reconstructions which may have effected dividend entitlement per share.
Dividend News Articles for CYCLOPHARM LIMITED(CYC)
|Cyclopharm (ASX:CYC) radiopharmaceutical leader - Finance News Network|
Cyclopharm (ASX:CYC) radiopharmaceutical leader Finance News Network
Cyclopharm (ASX:CYC) Managing Director & CEO, James McBrayer provides an update on its radiopharmaceutical products used in imaging, sales of ...
|3 speculative micro-cap shares that could make you a fortune - Motley Fool Australia|
3 speculative micro-cap shares that could make you a fortune Motley Fool Australia
As a big fan of micro-cap shares, I thought I'd take the time to review three fast-growing companies that could be about to take off. Below is a summary of three of ...
|3 cheap diversified micro-cap stocks for your portfolio - Motley Fool Australia|
3 cheap diversified micro-cap stocks for your portfolio Motley Fool Australia
Could these three companies deliver impressive gains for your portfolio?